Company intelligence / Profile preview

PhagoMed Biopharma

Vienna, Austria

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Before its acquisition by BioNTech, PhagoMed advanced a preclinical pipeline of phage cocktails and recombinant endolysins against biofilm-associated Staphylococcus aureus implant infections and Gardnerella-driven bacterial vaginosis, with IND/Phase 1–2a entry planned around 2021–2022 but with no publicly reported clinical trial readouts yet.[2][4][8]

Therapeutic areas: Women's HealthInfectious Diseases
Modalities: Microbial therapyProteinRecombinant protein
Industry: Biotech

Partnerships

Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures[3]Justus Liebig University Giessen[3]Ghent University[3]EIT Health (Catapult and Gold Track programs)[1][7]

Beyond the preview

Go deeper on PhagoMed Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PhagoMed Biopharma.

Explore the full profile